Cortexin Evidence Guide
Cortexin has Phase 3-level clinical use in Russia but the evidence base is almost entirely from Russian-language publications within a regulatory context that does not meet ICH GCP standards. Independent Western replication is absent. It is not a starting point for researchers who require independently validated evidence. Of the Cognitive & Nootropic compounds, cerebrolysin has significantly more independently replicated RCT data.
Our Take
Cortexin has Phase 3-level clinical use in Russia but the evidence base is almost entirely from Russian-language publications within a regulatory context that does not meet ICH GCP standards. Independent Western replication is absent. It is not a starting point for researchers who require independently validated evidence. Of the Cognitive & Nootropic compounds, cerebrolysin has significantly more independently replicated RCT data.
- Evidence context
- Russian clinical neurology practice context only; neuroprotective polypeptide research
- Evidence grade
- Level C
- Confidence
- Low
- Reference context
- Reported research reference: No reliable protocol for researchers outside the Russian clinical context
Benefits and Evidence
- Cognitive Recovery After Stroke: Level C, includes human evidence - Russian clinical trials report improved cognitive scores (MMSE, MoCA) and faster neurological recovery in ischemic stroke patients treated with Cortexin as adjunct therapy.
- Pediatric Neurodevelopment: Level C, includes human evidence - Studies in children with developmental delays and perinatal CNS damage show improvements in speech, motor coordination, and cognitive testing with Cortexin treatment.
- Neuroprotection: Level C, mostly non-human evidence - Animal models demonstrate reduced infarct volume, preserved blood-brain barrier integrity, and decreased neuronal apoptosis following Cortexin administration after experimental ischemia.
Side Effects and Warnings
- Injection site pain
- Allergic reactions (rare)
- Insomnia (if administered late in the day)
- Mild headache
- Not approved outside of Russia and CIS countries
- Derived from animal brain tissue - theoretical prion disease risk
- Clinical evidence is primarily from Russian-language publications with limited independent verification
- Contraindicated in known hypersensitivity to animal-derived proteins
Research Dosage References
- <strong>Intramuscular</strong> - 10 mg/day (adults), 5 mg/day (children) - Daily for 10 days; courses repeated 2-4 times per year - Dissolved in 1-2 mL water for injection or 0.5% procaine. Morning administration preferred to avoid insomnia.
Mechanism of Action
Cortexin contains a standardized mixture of neuropeptides that exhibit tissue-specific bioregulatory activity in the cerebral cortex. It normalizes the balance between excitatory (glutamate) and inhibitory (GABA) neurotransmission, enhances BDNF and NGF expression, activates superoxide dismutase and glutathione peroxidase antioxidant systems, stabilizes neuronal membranes by regulating lipid peroxidation, and modulates calcium channel activity to reduce excitotoxicity. These combined effects provide neuroprotection and support cognitive recovery.
Legal Status
Approved as a prescription medication in Russia and some CIS countries. It is not FDA-approved in the United States and is not approved in the European Union.
Primary Sources
- Cortexin in the treatment of ischemic stroke: a multicenter randomized controlled trial. Zhurnal Nevrologii i Psikhiatrii, 2012.
- Neuroprotective effects of cortexin in experimental cerebral ischemia. Bulletin of Experimental Biology and Medicine, 2009.
Quick Answers
Where is the strongest evidence for Cortexin?
Cortexin has Phase 3-level clinical use in Russia but the evidence base is almost entirely from Russian-language publications within a regulatory context that does not meet ICH GCP standards. Independent Western replication is absent. It is not a starting point for researchers who require independently validated evidence. Of the Cognitive & Nootropic compounds, cerebrolysin has significantly more independently replicated RCT data. Evidence context: Russian clinical neurology practice context only; neuroprotective polypeptide research.
What are the main side effects of Cortexin?
Cortexin side effects and warning signals include Injection site pain, Allergic reactions (rare), Insomnia (if administered late in the day), Mild headache, and Not approved outside of Russia and CIS countries.
What evidence level is Cortexin?
Cortexin is rated Level C; the listed research status is Approved Outside US.